Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02138188
Other study ID # ISP-DT1-ITA13 (CE-2393)
Secondary ID
Status Recruiting
Phase N/A
First received May 12, 2014
Last updated May 13, 2014
Start date September 2013
Est. completion date April 2016

Study information

Verified date May 2014
Source Universita di Verona
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Observational

Clinical Trial Summary

The Continuous Subcutaneous Insulin Infusion (CSII) might have an impact on psychological distress and some psychological factors might be predictors of metabolic control; however, very few studies conducted so far were specifically focused on the psychological aspects of CSII therapy in adults affected by T1DM.


Description:

The aim of this project is to study the psychological effect of Continuous Subcutaneous Insulin Infusion (CSII) in a cohort of type 1 diabetic patients and to explore the influence of psychological factors (coping style, locus of control, self-efficacy) on glycaemic control. A sample of 36 type 1 diabetic patients will be recruited at Endocrinology, Diabetes and Metabolism Division of Verona City Hospital.

Among T1DM patients routinely followed by our Institution the study will be proposed to those starting the CSII therapy based on the inclusion and exclusion criteria.

Each study participants will provide a written informed consent and will undergo a set of 4 psychological evaluation assessing depression, anxiety, self-efficacy, perceived interference caused by diabetes, family support, locus of control and coping strategies on top of routine medical examination and laboratory testing for outcome measures at baseline and after 6, 12 and 24 months after study entry.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date April 2016
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Type 1 Diabetes

- Transition to CSII

- Age >18 years

Exclusion Criteria:

- Current schizophrenia/ psychotic disorders, bipolar disorders, addictive disorders, personality disorders

- Pregnancy

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Division of Endocrinology, Diabetes and Metabolism-Department of Medicine-AOUI Verona Verona

Sponsors (1)

Lead Sponsor Collaborator
Universita di Verona

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline glycosylated haemoglobin (HbA1c) at 6th, 12th and 24th months after transition to CSII. Glycosylated haemoglobin (HbA1c) is a lab test that shows the average level of blood glucose over the previous 3 months. HbA1c is used in the present study as measure of the glycaemic control: it will be assessed at baseline, after 6, 12 and 24 months. Baseline, 6, 12 and 24 months No
Secondary Change from baseline glucose variability as measured by standard deviation (SD) and coefficient of variation (CV) of capillary blood glucose test [mg/dL] at 6th, 12th and 24th months after transition to CSII. SD and CV will be calculated from daily measurements of at least 3 capillary blood glucose measurements representative of pre- and post-meal glucose excursion over the entire day. Baseline, 6, 12, 24 months No
Secondary Change from baseline glucose variability as measured by the Low Blood Glucose Index (%LBGI) at 6th, 12th and 24th months after transition to CSII. The LBGI is a validated percentage index of frequency and amplitude of glucose excursions below a conventional glucose threshold set at 6.25 mmol/L and allows the normalization of non-Gaussian distributions of both capillary and interstitial blood glucose measurements collected over a pre-determined time frame. Baseline, 6, 12, 24 months No
Secondary Change from baseline glucose variability as measured by High Blood Glucose Index (%HBGI) at 6th, 12th and 24th months after transition to CSII. The HBGI is a validated percentage index of frequency and amplitude of glucose excursions over a conventional glucose threshold set at 6.25 mmol/L, as previously described. Baseline, 6, 12, 24 months No
Secondary Change from baseline depressive symptoms at 6th,12th and 24th months (BDI-II score) The Beck Depression Inventory II is a 21-item questionnaire developed to assess the intensity of depression as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV). The BDI-II items include cognitive symptoms such as sadness and pessimism, affective symptoms such as loss of pleasure and loss of interest, somatic symptoms such as loss of energy, appetite changes and changes in sleep pattern. The BDI-II is calculated by summing the ratings for the 21 items. The 4-point scale ranges from 0 to 3 for each item. The maximum total score is 63. The measurement of outcome variables will be conducted 6, 12 and 24 months after transition to CSII.
The difference of the BDI-II scores among baseline, at 6,12 and 24 months will be also calculated.
Baseline, 6, 12, 24 months No
Secondary Change from baseline anxiety symptoms at 6th,12th and 24th months (BAI score) The Beck Anxiety Inventory is a 21- item questionnaire developed to assess the severity of anxiety by describing its emotional, physiological and cognitive symptoms. The 4-point scale of BAI score ranges from 0 to 3 for each item, with a maximum total score of 63. Outcome variables will be evaluated at 6, 12 and 24 months after transition to CSII. The difference of the BAI scores among baseline, 6, 12 and 24 months will be also calculated. Baseline, 6, 12, 24 months No
Secondary Change from baseline general perceptions of diabetes at 6th, 12th and 24th months (MDQ Section 1 score) The Multidimensional Diabetes Questionnaire (MDQ) was designed to provide a comprehensive assessment of diabetes-related cognitive and social factors. It includes 41 items subcategorized in three sections. The first section assesses the general perceptions of diabetes and related social support. It is comprised of three scales. These scales targets:
perceived interference caused by diabetes to daily activities, work and social activities (9 items); perceived severity of diabetes (3 items); perceived diabetes-related social support from a significant other such as family, friends and health professionals (4 items).
Responses were rated on 7-point rating scales (from 0 to 6), with higher scores indicating higher levels of perceived interference, social support and severity.
Baseline, 6, 12, 24 months No
Secondary Change from baseline family support at 6th, 12th and 24th months (MDQ section II score) This section of the MDQ measures social incentives in relation to self-care activities. The scales included in this section were designed to measure the frequency of positive reinforcing behaviour (8 items) and the frequency of non supportive behaviours (4 items). Subjects recorded their responses on 7-point Likert scales (from 0 to 6) with higher scores indicating higher levels of positive and negative reinforcement behaviours. Baseline, 6, 12 and 24 months No
Secondary Change from baseline Diabetes Self-Efficacy at 6th, 12th and 24th months (MDQ section III score) This section of the MDQ is used to assess self-efficacy expectancies (7 items) and outcome expectancies (6 items). The self-efficacy scale measured patients' confidence in their ability to perform behaviors specific to the diabetes self-care activities. Responses were rated on a 0 to 100 rating scale. The outcome expectancies scale assessed patients' perceptions of the effect of diabetes self-care behaviors on metabolic control. Responses were rated on a 0 to 100 rating scale. Baseline, 6, 12, 24 months No
Secondary Determination of Health Locus of Control (MHLC) at Baseline The multidimensional Health Locus of Control Scale consists of three subscale with six items each. The three subscales are: Internal Health Locus of Control (IHLC), Powerful Others Externality (PHLC), Chance Health Locus of Control (CHLC). Baseline No
Secondary Measures of Coping Strategies at Baseline Coping strategies will be measured with the Coping Orientation to Problems Experienced-New Italian Version (COPE-NVI). The instrument is a multidimensional 60-items coping inventory to assess the different ways in which people respond to stress and it was developed to assess a broad range of coping responses. Baseline No
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany